Respiratory Syncytial Virus Infections
"Respiratory Syncytial Virus Infections" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.
| Descriptor ID |
D018357
|
| MeSH Number(s) |
C02.782.580.600.620.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus Infections".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus Infections".
This graph shows the total number of publications written about "Respiratory Syncytial Virus Infections" by people in this website by year, and whether "Respiratory Syncytial Virus Infections" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 2 | 3 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus Infections" by people in Profiles.
-
Ginkgolic acid inhibits orthopneumo- and metapneumo- virus infectivity. Sci Rep. 2024 04 08; 14(1):8230.
-
Infants Admitted to US Intensive Care Units for RSV Infection During the 2022 Seasonal Peak. JAMA Netw Open. 2023 08 01; 6(8):e2328950.
-
Healthcare-Associated Respiratory Syncytial Virus in Children's Hospitals. J Pediatric Infect Dis Soc. 2023 May 31; 12(5):265-272.
-
Factors Associated With Severe Illness in Patients Aged <21 Years Hospitalized for COVID-19. Hosp Pediatr. 2022 09 01; 12(9):760-783.
-
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients. Clin Infect Dis. 2020 12 31; 71(11):2777-2786.
-
A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Lower Respiratory Tract. Clin Infect Dis. 2020 12 31; 71(11):2787-2795.
-
Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections. Infect Control Hosp Epidemiol. 2018 04; 39(4):485-487.
-
Transiently Thermoresponsive Acetal Polymers for Safe and Effective Administration of Amphotericin B as a Vaccine Adjuvant. Bioconjug Chem. 2018 03 21; 29(3):748-760.
-
The performance of Luminex ARIES® Flu A/B & RSV and Cepheid Xpert® Flu/RSV XC for the detection of influenza A, influenza B, and respiratory syncytial virus in prospective patient samples. J Clin Virol. 2017 10; 95:84-85.
-
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data. Leuk Lymphoma. 2018 01; 59(1):256-258.